Accelerated Detection of Mycolactone Production and Response to Antibiotic Treatment in a Mouse Model of Mycobacterium ulcerans Disease

PLoS Neglected Tropical Diseases

Volumn 8, Issue 1, 2014, Pages 52-

  Converse, Paul J ^a   Xing, Yalan ^b   Kim, Ki Hyun ^b   Tyagi, Sandeep ^a   Li, Si Yang ^a   Almeida, Deepak V ^a   Nuermberger, Eric L ^a   Grosset, Jacques H ^a   Kishi, Yoshito ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL TOXIN; CLARITHROMYCIN; MYCOLACTONE; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; MACROLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BURULI ULCER; COLONY FORMING UNIT; CONTROLLED STUDY; FLUORESCENCE; FOOT PAD; HISTOPATHOLOGY; LEG SWELLING; MASS SPECTROMETRY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; THIN LAYER CHROMATOGRAPHY; ULTRAVIOLET RADIATION; ANIMAL; DRUG MONITORING; METABOLISM; METHODOLOGY; MYCOBACTERIUM ULCERANS;

ANIMALS; ANTI-BACTERIAL AGENTS; BURULI ULCER; CHROMATOGRAPHY, THIN LAYER; DRUG MONITORING; MACROLIDES; MICE; MYCOBACTERIUM ULCERANS;

EID: 84893803833     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002618     Document Type: Article

References (35)

1. Converse PJ, Nuermberger EL, Almeida DV, Grosset JH, (2011) Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? Future Microbiology 6: 1185-1198.
2. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-857.
3. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, et al. (2004) Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A 101: 1345-1349.
4. Fenner F, (1956) The pathogenic behavior of Mycobacterium ulcerans and Mycobacterium balnei in the mouse and the developing chick embryo. Am Rev Tuberc 73: 650-673.
5. Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, et al. (2001) Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 45: 3109-3112.
6. Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J, (2002) Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 46: 3193-3196.
7. Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J, (2000) Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 44: 2367-2372.
8. Chauty A, Ardant M-F, Adeye A, Euverte H, Guedenon A, et al. (2007) Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli Ulcer (Mycobacterium ulcerans Disease). Antimicrob Agents Chemother 51: 4029-4035.
9. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, et al. (2005) Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans. Antimicrob Agents Chemother 49: 3182-3186.
10. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. (2010) Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. The Lancet 375: 664-672.
11. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, et al. (2010) Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 54: 3678-3685.
12. George KM, Pascopella L, Welty DM, Small PL, (2000) A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 68: 877-883.
13. Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T, (2008) Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep 25: 447-454.
14. Hong H, Gates PJ, Staunton J, Stinear T, Cole ST, et al. (2003) Identification using LC-MSn of co-metabolites in the biosynthesis of the polyketide toxin mycolactone by a clinical isolate of Mycobacterium ulcerans. Chem Commun (Camb) pp. 2822-2823.
15. Hong H, Spencer JB, Porter JL, Leadlay PF, Stinear T, (2005) A novel mycolactone from a clinical isolate of Mycobacterium ulcerans provides evidence for additional toxin heterogeneity as a result of specific changes in the modular polyketide synthase. Chembiochem 6: 643-648.
16. Kishi Y, (2011) Chemistry of mycolactones, the causative toxins of Buruli ulcer. Proc Natl Acad Sci U S A 108: 6703-6708.
17. Spangenberg T, Kishi Y, (2010) Highly sensitive, operationally simple, cost/time effective detection of the mycolactones from the human pathogen Mycobacterium ulcerans. Chemical Communications 46: 1410-1412.
18. Demangel C, Stinear TP, Cole ST, (2009) Buruli ulcer: Reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol 7: 50-60.
19. Song F, Fidanze S, Benowitz AB, Kishi Y, (2002) Total synthesis of the mycolactones. Org Lett 4: 647-650.
20. Song F, Fidanze S, Benowitz AB, Kishi Y, (2007) Total Synthesis of Mycolactones A and B. Tetrahedron 63: 5739-5753.
21. Martins TG, Gama JB, Fraga AG, Saraiva M, Silva MT, et al. (2012) Local and Regional Re-Establishment of Cellular Immunity during Curative Antibiotherapy of Murine Mycobacterium ulcerans Infection. PLoS ONE 7: e32740.
22. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, et al. (2005) Infection with Mycobacterium ulcerans Induces Persistent Inflammatory Responses in Mice. Infect Immun 73: 6299-6310.
23. Ruf MT, Schutte D, Chauffour A, Jarlier V, Ji B, et al. (2012) Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model. Antimicrob Agents Chemother 56: 687-696.
24. Sarfo FS, Converse PJ, Almeida DV, Zhang J, Robinson C, et al. (2013) Microbiological, Histological, Immunological, and Toxin Response to Antibiotic Treatment in the Mouse Model of Mycobacterium ulcerans Disease. PLoS Negl Trop Dis 7: e2101.
25. Torrado E, Adusumilli S, Fraga AG, Small PLC, Castro AG, et al. (2007) Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 75: 3979-3988.
26. Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, et al. (2007) Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 75: 977-987.
27. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, et al. (2011) Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice. PLoS Negl Trop Dis 5: e933.
28. Chauty A, Ardant M-Fß, Marsollier L, Pluschke G, Landier J, et al. (2011) Oral Treatment for Mycobacterium ulcerans Infection: Results From a Pilot Study in Benin. Clinical Infectious Diseases 52: 94-96.
29. Ji B, Chauffour A, Robert J, Jarlier V, (2008) Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 52: 1912-1916.
30. Pettit JHS, Marchette NJ, Rees RJW, (1966) Mycobacterium ulcerans infection. Clinical and bacteriological study of the first cases recognized in South East Asia. British Journal of Dermatology 78: 187-197.
31. Converse PJ, Almeida DV, Nuermberger EL, Grosset JH, (2011) BCG-Mediated Protection against Mycobacterium ulcerans Infection in the Mouse. PLoS Neglected Tropical Diseases 5: e985.
32. Zhang T, Li S-Y, Converse PJ, Almeida DV, Grosset JH, et al. (2011) Using Bioluminescence To Monitor Treatment Response in Real Time in Mice with Mycobacterium ulcerans Infection. Antimicrob Agents Chemother 55: 56-61.
33. Beissner M, Herbinger KH, Bretzel G, (2010) Laboratory diagnosis of Buruli ulcer disease. Future Microbiol 5: 363-370.
34. Beissner M, Symank D, Phillips RO, Amoako YA, Awua-Boateng N-Y, et al. (2012) Detection of Viable Mycobacterium ulcerans in Clinical Samples by a Novel Combined 16S rRNA Reverse Transcriptase/IS2404 Real-Time qPCR Assay. PLoS Negl Trop Dis 6: e1756.
35. Almeida DV, Converse PJ, Li SY, Tyagi S, Nuermberger EL, et al. (2013) Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis 7: e2085.